Physician profile
Robert J Lin
NPI 1770742090
$498.67
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $84.96 · 2021: $124 · 2022: $116 · 2023: $143 · 2024: $31.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $173.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $88.04 | 2023-2024 | |
| Aveo Pharmaceuticals, INC. | $57.66 | 2021-2022 | |
| Blueprint Medicines Corporation | $45.41 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.33 | 2020-2022 | |
| Eisai INC. | $37.70 | 2023 | |
| Adc Therapeutics America, INC. | $30.10 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.43 | 2023 | Alunbrig |
| Pharmacyclics LLC, An Abbvie Company | $25.03 | 2020 | |
| Incyte Corporation | $24.06 | 2020 | |
| Epizyme, INC. | $22.17 | 2021 | |
| Tersera Therapeutics LLC | $19.92 | 2021 | |
| Foundation Medicine, INC. | $19.55 | 2023 | |
| Karyopharm Therapeutics INC. | $17.39 | 2020 | |
| Rigel Pharmaceuticals, INC. | $14.61 | 2021 | |
| Lilly USA, LLC | $14.24 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.